| 46998-1 |
TCRB & Immunoglobulin heavy chain gene rearrangements |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
TCRB and HC gene rearrangements in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.REARRANGE |
|
46998-1 |
|
Molgen |
|
|
Both |
|
|
|
0 |
TCRB+HC gene Rear Bld/T |
|
|
|
N |
|
B-cell Clonality; Blood; Chains; Chn; Clonality; Document; Finding; Findings; Genetics; HC gene Rear; Heredity; Heritable; IgH; Immune globulin; Immuno; Immunoglob; Immunoglobin; Imunoglbon; Imunoglobn; Inherited; Leukemia; Lymphoma; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.REARRANGEMENTS; PCR; Point in time; Random; Rearr; Rearrangement; TCRB+HC gene Rear; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 46999-9 |
Bacterial vaginosis & vaginitis rRNA panel |
- |
Vag |
Pt |
- |
Probe |
|
ACTIVE |
Bacterial vaginosis and vaginitis rRNA panel - Vaginal fluid by Probe |
|
MIN |
DefinitionDescription |
|
|
|
Not detected or detected |
|
|
|
|
|
PANEL.MICRO |
|
46999-9 |
|
Probe |
|
|
Order |
|
|
|
0 |
Vaginosis/itis rRNA Pnl Vag Probe |
|
|
|
N |
|
Bact; DNA NUCLEIC ACID PROBE; DNA probe; Genital vaginal; Gyn; Gynecology; ID; Infectious Disease; InfectiousDisease; Microbiology; OB; ObGyn; Obstetrics; Pan; PANEL.MICROBIOLOGY; Panl; Pnl; Point in time; Random; ribosomal RNA; Vag fld; Vag fluid; Vagina; Vaginal fluid; Vaginal pathogens; Vaginosis/itis rRNA Pnl |
2.73 |
2.19 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 47-1 |
Bacampicillin |
Susc |
Isolate |
Pt |
Qn |
MLC |
|
ACTIVE |
Bacampicillin [Susceptibility] by Minimum lethal concentration (MLC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
47-1 |
|
MLC |
|
|
Observation |
|
|
|
0 |
Bacampicillin Islt MLC |
|
|
|
Y |
|
Albaxin; Ambacamp; Ambaxin; Amplibac; ANTIBIOTIC SUSCEPTIBILITIES; AST; Bacacil; Bacampicin; Bacocil; Carampicillin; ID; Infectious Disease; InfectiousDisease; Islt; Isol; MBC; Minimum bactericidal concentration; Minimum lethal concentration; Penglobe; Point in time; QNT; Quan; Quant; Quantitative; Random; Sprectrobid; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Velbacampin |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 470-5 |
Sulfamethoxazole |
Titr |
Isolate+Ser |
Pt |
SemiQn |
SBT |
|
ACTIVE |
Sulfamethoxazole [Susceptibility] by Serum bactericidal titer |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
ABXBACT |
|
470-5 |
|
SBT |
|
|
Observation |
|
|
|
0 |
Sulfamethoxazole Titr SBT |
|
|
|
|
|
Acetylsulfamethoxazole; ANTIBIOTIC SUSCEPTIBILITIES; c203; c223; C61; Dilution factor; Dilution Factor (Titer); Gantanol; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Point in time; Random; Sequence based typing; Serum; SERUM BACTERICIDAL TITER; Serum killing test; SmQn; SMX; SR; Sulfa; Sulfamethox; Titer; Titered; Titre; Ttr |
2.75 |
1 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 4700-1 |
HLA-A34(10) |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-A34(10) [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4700-1 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A34(10) Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47000-5 |
Candida sp rRNA |
PrThr |
Vag |
Pt |
Ord |
Probe |
|
ACTIVE |
Candida sp rRNA [Presence] in Vaginal fluid by Probe |
|
MIN |
DefinitionDescription |
|
|
|
Not detected or detected |
|
|
|
|
|
MICRO |
|
47000-5 |
|
Probe |
|
|
Both |
|
|
|
0 |
Candida rRNA Vag Ql Probe |
|
|
|
N |
|
Cand; Candidiasis; DNA NUCLEIC ACID PROBE; DNA probe; Genital vaginal; Gyn; Gynecology; ID; Infectious Disease; InfectiousDisease; Microbiology; Monilia; OB; ObGyn; Obstetrics; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; ribosomal RNA; Screen; species; spp; Thrush; UniversalLabOrders; Vag fld; Vag fluid; Vagina; Vaginal fluid |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
246 |
| 47001-3 |
Brucella sp Ag |
PrThr |
XXX |
Pt |
Ord |
Aggl |
|
ACTIVE |
Brucella sp Ag [Presence] in Specimen by Agglutination |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
47001-3 |
|
Aggl |
|
|
Both |
|
|
|
0 |
Brucella Ag Spec Ql Aggl |
|
|
|
N |
|
Agg; Agglut; Agglutination; Antigen; Antigens; Bruc; Brucellosis; ID; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; species; spp; To be specified in another part of the message; Unspecified |
2.69 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47002-1 |
Varicella zoster virus DNA |
NCnc |
CSF |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Varicella zoster virus DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
47002-1 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
VZV DNA # CSF NAA+probe |
|
|
|
N |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; Amplif; Amplification; Amplified; Cerebral spinal fluid; Cerebrospinal Fl; Chicken pox; Chicken pox virus; Chickenpox; Cnt; Count; Count/volume; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Herpes zoster; HHV-3; Human herpesvirus 3; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Neuro; Neurology; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Shingles; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load; VZ; VZV; Zoster |
2.73 |
2.19 |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
| 47003-9 |
Varicella zoster virus DNA |
NCnc |
Ser/Plas |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Varicella zoster virus DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
47003-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
VZV DNA # SerPl NAA+probe |
|
|
|
N |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; Amplif; Amplification; Amplified; Chicken pox; Chicken pox virus; Chickenpox; Cnt; Count; Count/volume; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Herpes zoster; HHV-3; Human herpesvirus 3; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; SerP; SerPl; SerPlas; Serum; Serum or plasma; Shingles; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load; VZ; VZV; Zoster |
2.73 |
2.19 |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
| 47004-7 |
6-Monoacetylmorphine.free |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
6-monoacetylmorphine free [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
47004-7 |
|
Confirm |
|
|
Both |
|
|
|
0 |
6MAM Free Ur Cfm-mCnc |
|
|
|
N |
|
6 MAM; 6 mono acetyl morphine; 6-acetylmorphine; 6MAM; 6MAM Free; Acetylmorphine; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; FR; GCMS; Heroin metabolite; LC/MS/MS; Level; MAM; Mass concentration; Non-protein bound; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.19 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 47005-4 |
Spermatozoa Ab.IgM/Spermatozoa |
NFr |
Ser |
Pt |
Qn |
Immunobead |
|
ACTIVE |
Spermatozoa IgM Ab/Spermatozoa in Serum by Immunobead |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
FERT |
|
47005-4 |
|
Immunobead |
|
|
Both |
|
|
|
0 |
Sperm IgM NFr Ser IBT |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; FERTILITY TESTING; Genitourinary; GU; IBA; IBT; Immune globulin M; Immunoglobulin M; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; Sperm; SR; URO; Urology |
2.79 |
2.19 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 47006-2 |
Spermatozoa Ab.IgG/Spermatozoa |
NFr |
Ser |
Pt |
Qn |
Immunobead |
|
ACTIVE |
Spermatozoa IgG Ab/Spermatozoa in Serum by Immunobead |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
FERT |
|
47006-2 |
|
Immunobead |
|
|
Both |
|
|
|
0 |
Sperm IgG NFr Ser IBT |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; FERTILITY TESTING; Genitourinary; GU; IBA; IBT; Immune globulin G; Immunoglobulin G; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; Sperm; SR; URO; Urology |
2.79 |
2.19 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 47007-0 |
Spermatozoa Ab.IgA/Spermatozoa |
NFr |
Ser |
Pt |
Qn |
Immunobead |
|
ACTIVE |
Spermatozoa IgA Ab/Spermatozoa in Serum by Immunobead |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
FERT |
|
47007-0 |
|
Immunobead |
|
|
Both |
|
|
|
0 |
Sperm IgA NFr Ser IBT |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; FERTILITY TESTING; Genitourinary; GU; IBA; IBT; Immune globulin A; Immunoglobulin A; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; Sperm; SR; URO; Urology |
2.79 |
2.19 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 47008-8 |
Platelet associated Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Platelet associated IgG Ab [Presence] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
Negative |
|
|
|
|
|
SERO |
|
47008-8 |
|
IA |
|
|
Both |
|
|
|
0 |
PA IgG Ser Ql IA |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Assoc; Autoantibodies; Autoantibody; Direct platelet antibody; EIA; ELFA; ELISA; Enzyme immunoassay; Hematology; Heme; IAA; Immune globulin G; Immunoglobulin G; MEIA; Ordinal; PA; PAIgG; Pl; Platelet auto-antibodies; Platelets; Platelt; Plt; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SR; SUDS; Thrombocyte; Thrombocytes |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47009-6 |
BCL6 Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
BCL6 Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATH |
|
47009-6 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
BCL6 Ag Tiss Ql ImStn |
|
|
|
N |
|
Antigen; Antigens; BCL-6; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; PATHOLOGY; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4701-9 |
HLA-A36 |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-A36 [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4701-9 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A36 Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47010-4 |
Ber-EP4 Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
Ber-EP4 Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATH |
|
47010-4 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
BER-EP4 Ag Tiss Ql ImStn |
|
|
|
N |
|
Antigen; Antigens; EpCAM; Human epithelial antigen; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; PATHOLOGY; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47011-2 |
Calretinin Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
Calretinin Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATH |
|
47011-2 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
Calretinin Ag Tiss Ql ImStn |
|
|
|
N |
|
Antigen; Antigens; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; PATHOLOGY; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47012-0 |
Cancer Ag 72-4 |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
Cancer Ag 72-4 [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATH |
|
47012-0 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
Cancer Ag72-4 Tiss Ql ImStn |
|
|
|
N |
|
CA; CA 72-4; Cancer Ag72-4; Carbohydrate antigen; Carbohydrate antigen 72-4; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; PATHOLOGY; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tag-72; Tissue; Tissue, unspecified; Tumor marker |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47013-8 |
CD1a Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
CD1a Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
47013-8 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
CD1a Ag Tiss Ql ImStn |
|
|
|
N |
|
Antigen; Antigens; CELL MARKERS; HTA1; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; Point in time; PR; QL; Qual; Qualitative; R4; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47014-6 |
CD21 Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
CD21 Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
47014-6 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
CD21 Ag Tiss Ql ImStn |
|
|
|
N |
|
Antigen; Antigens; B2; B-2; C3d receptor; CELL MARKERS; CR2; EBV-R; Epstein Barr virus receptor; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47015-3 |
CD31 Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
CD31 Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
47015-3 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
CD31 Ag Tiss Ql ImStn |
|
|
|
N |
|
Antigen; Antigens; CELL MARKERS; Endocam; GPiia'; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; PECAM-1; platelet endothelial cell adhesion molecule; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47016-1 |
CD4 Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
CD4 Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
47016-1 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
CD4 Ag Tiss Ql ImStn |
|
|
|
N |
|
Antigen; Antigens; CELL MARKERS; Helper T cells; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Inducer T cells; L3T4; Leu3; Leu-3; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; T4; T-4; Tissue; Tissue, unspecified; W3/25 |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47017-9 |
CD68 Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
CD68 Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
47017-9 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
CD68 Ag Tiss Ql ImStn |
|
|
|
N |
|
Antigen; Antigens; CELL MARKERS; gp110; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Macrosialin; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47018-7 |
CD79a Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
CD79a Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
47018-7 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
CD79a Ag Tiss Ql ImStn |
|
|
|
N |
|
Antigen; Antigens; CELL MARKERS; Ig alpha; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; MB1; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
